Drug Information

Drug General Information
Drug ID
D0S9BH
Former ID
DCL000588
Drug Name
Ozarelix
Indication Prostate disease [ICD10:N42.9] Phase 2 [531030]
Company
Spectrum
Target and Pathway
Target(s) Gonadotropin-releasing hormone receptor Target Info Modulator [531030]
KEGG Pathway Neuroactive ligand-receptor interaction
GnRH signaling pathway
NetPath Pathway IL1 Signaling Pathway
IL2 Signaling Pathway
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Reactome Hormone ligand-binding receptors
G alpha (q) signalling events
WikiPathways Gastrin-CREB signalling pathway via PKC and MAPK
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 531030Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate. 2010 Sep 1;70(12):1340-9.
Ref 531030Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate. 2010 Sep 1;70(12):1340-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.